Rossella Elisei
Pisa endocrinologist who led EXAM, the trial that established cabozantinib for progressive medullary thyroid cancer, and who has studied RET mutations in the disease for decades.
Overview
Rossella Elisei is professor of endocrinology at the University of Pisa, one of the largest thyroid cancer centres in Europe. She was first author of the 2013 Journal of Clinical Oncology report of EXAM, the phase 3 trial in which cabozantinib lengthened progression-free survival compared with placebo in progressive metastatic medullary thyroid cancer, leading to its approval. Her research covers the prognostic value of RET mutations and calcitonin doubling time.
Similar pages
not linked directly; found by shared links- PersonJulien Hadoux
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, targeted-therapy, trialist.
- PersonVivek Subbiah
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, targeted-therapy, trialist.
- PersonMarcia S. Brose
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
- PersonSamuel A. Wells Jr.
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, trialist.
- PersonLori J. Wirth
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
- PersonAleksandar Sekulic
Shares the tags targeted-therapy, trialist.
- PersonAlice T. Shaw
Shares the tags targeted-therapy, trialist.
- PersonAndrea Sartore-Bianchi
Shares the tags targeted-therapy, trialist.